CN114366720A - 一种防滥用的三唑仑口服片剂及其制备方法 - Google Patents
一种防滥用的三唑仑口服片剂及其制备方法 Download PDFInfo
- Publication number
- CN114366720A CN114366720A CN202111510162.6A CN202111510162A CN114366720A CN 114366720 A CN114366720 A CN 114366720A CN 202111510162 A CN202111510162 A CN 202111510162A CN 114366720 A CN114366720 A CN 114366720A
- Authority
- CN
- China
- Prior art keywords
- triazolam
- coating
- tablet
- parts
- solvent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Anesthesiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
成分 | 用量(g) |
HPMC E5 | 10 |
水 | 90 |
成分 | 用量(g) |
乙醇 | 188 |
苯甲地那铵 | 1 |
异硫氰酸烯丙酯 | 1 |
亮蓝 | 1 |
HPC EF | 9 |
成分 | 用量(g) |
薄膜包衣预混剂Y-1-7000 | 18 |
水 | 82 |
项目 | 限度 | 结果 |
含量 | 90%~110% | 98.4% |
含量均匀度 | A+2.2S≤15.0 | 7.94 |
仪器 | FADT-1202RC自动取样溶出仪 |
溶出介质 | 水 |
介质体积(ml) | 200 |
温度(℃) | 37 |
转速(rpm) | 75(小杯法搅拌桨) |
测定 | 高效液相色谱法 |
取样体积(ml) | 10 |
取样时间点(min) | 30,60,90,120,180,240,480 |
时间 | 溶出量 | SD | RSD |
0 | 0 | - | - |
30 | 26.28% | 4.77% | 5.91% |
60 | 45.01% | 4.29% | 5.11% |
90 | 60.77% | 4.16% | 4.84% |
120 | 72.59% | 4.00% | 4.53% |
180 | 86.77% | 4.17% | 4.66% |
240 | 90.24% | 4.55% | 4.97% |
480 | 90.68% | 4.51% | 4.84% |
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111510162.6A CN114366720B (zh) | 2021-12-11 | 2021-12-11 | 一种防滥用的三唑仑口服片剂及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111510162.6A CN114366720B (zh) | 2021-12-11 | 2021-12-11 | 一种防滥用的三唑仑口服片剂及其制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114366720A true CN114366720A (zh) | 2022-04-19 |
CN114366720B CN114366720B (zh) | 2023-07-21 |
Family
ID=81139339
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202111510162.6A Active CN114366720B (zh) | 2021-12-11 | 2021-12-11 | 一种防滥用的三唑仑口服片剂及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114366720B (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1389208A (zh) * | 2002-07-11 | 2003-01-08 | 中国药科大学 | 苯二氮卓类药物口服脉冲释药系统及其制备方法 |
US20030064099A1 (en) * | 2001-08-06 | 2003-04-03 | Benjamin Oshlack | Pharmaceutical formulation containing bittering agent |
US20040228802A1 (en) * | 2003-05-12 | 2004-11-18 | Rong-Kun Chang | Drug formulations having reduced abuse potential |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US20100239662A1 (en) * | 2008-12-16 | 2010-09-23 | Miloud Rahmouni | Misuse preventative, controlled release formulation |
US20140010874A1 (en) * | 2010-12-23 | 2014-01-09 | Purdue Pharma L.P. | Tamper Resistant Solid Oral Dosage Forms |
WO2016120892A1 (en) * | 2015-01-29 | 2016-08-04 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent controlled release solid dosage form |
-
2021
- 2021-12-11 CN CN202111510162.6A patent/CN114366720B/zh active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030064099A1 (en) * | 2001-08-06 | 2003-04-03 | Benjamin Oshlack | Pharmaceutical formulation containing bittering agent |
CN1389208A (zh) * | 2002-07-11 | 2003-01-08 | 中国药科大学 | 苯二氮卓类药物口服脉冲释药系统及其制备方法 |
US20040228802A1 (en) * | 2003-05-12 | 2004-11-18 | Rong-Kun Chang | Drug formulations having reduced abuse potential |
US20080069891A1 (en) * | 2006-09-15 | 2008-03-20 | Cima Labs, Inc. | Abuse resistant drug formulation |
US20100239662A1 (en) * | 2008-12-16 | 2010-09-23 | Miloud Rahmouni | Misuse preventative, controlled release formulation |
US20140010874A1 (en) * | 2010-12-23 | 2014-01-09 | Purdue Pharma L.P. | Tamper Resistant Solid Oral Dosage Forms |
WO2016120892A1 (en) * | 2015-01-29 | 2016-08-04 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent controlled release solid dosage form |
Also Published As
Publication number | Publication date |
---|---|
CN114366720B (zh) | 2023-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9884029B2 (en) | Morphine controlled release system | |
US9707179B2 (en) | Opioid polymer release system | |
JP6067100B2 (ja) | 即放性乱用抑止医薬組成物 | |
CN101594851B (zh) | 用于口服给药的酪氨酸激酶抑制剂的药物剂型 | |
US20040234602A1 (en) | Polymer release system | |
TW550071B (en) | Denaturants for sympathomimetic amine salts | |
JP2001500885A (ja) | 経口遅延型即時放出製剤及びその製造方法 | |
CN1762357B (zh) | 一种莫西沙星口服药物制剂及其制备方法 | |
CN104523686B (zh) | 盐酸阿考替胺药物制剂及其制备方法 | |
Williams et al. | Method to recover a lipophilic drug from hydroxypropyl methylcellulose matrix tablets | |
CN108853042B (zh) | 一种米氮平冻干口崩片及其制备方法和应用 | |
CN114366720B (zh) | 一种防滥用的三唑仑口服片剂及其制备方法 | |
WO2021023231A1 (zh) | 含硝羟喹啉的药物组合物、硝羟喹啉口服固体片剂及其制备方法和用途 | |
JP3496158B2 (ja) | トラネキサム酸配合ゼラチンカプセル製剤 | |
CN102462675A (zh) | 一种苯扎贝特缓释片及其制备方法 | |
Nandhakumar et al. | Formulation design and Evaluation of Extended-Release Tablets of Oxybutynin for Effective Management of Overactive Bladder Syndrome | |
CN101262857A (zh) | 3-(2-二甲基氨基甲基环己基)苯酚延迟制剂 | |
CN105982871A (zh) | 一种连翘苷元片剂 | |
CN114306262A (zh) | 米拉贝隆缓释片及其制备方法和质量检测方法 | |
CN103550182B (zh) | 一种肠溶缓释组合物 | |
Chaturvedi et al. | Comparative Evaluation Of Natural And Semisynthetic Superdisintegrants In The Formulation Of Orodispersible Tablets of Norfloxacin | |
CN112957335B (zh) | 一种乙酰氨基葡萄糖口腔崩解片及其制备方法 | |
WO2023173460A1 (zh) | 一种sglt-2抑制剂的药物组合物 | |
CN115154431B (zh) | 一种硝酸甘油片剂及其制备方法 | |
CN108685876A (zh) | 一种含有利培酮的口服膜状药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Xu Xiangyang Inventor after: Wang Jiayu Inventor after: Gu Tian Inventor after: Wang Huixian Inventor after: Jiang Zhuoling Inventor after: Gao Zizhen Inventor before: Wang Jiayu Inventor before: Gu Tian Inventor before: Wang Huixian Inventor before: Jiang Zhuoling Inventor before: Gao Zizhen Inventor before: Xu Xiangyang |
|
GR01 | Patent grant | ||
GR01 | Patent grant |